Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Videos|September 30, 2020
Mental Health and Medical Care Avoidance
Author(s)Judith Feld, MD, MPH, MMM, DLFAPA
Individuals who are anxious and depressed are more likely to avoid necessary medical care, even during a pandemic.
Advertisement
COVID-19 is putting unprecedented pressure on the United States’ healthcare system. But believe it or not, the pandemic is also leading some individuals to delay or even avoid necessary treatment.
Why? The answer may be mental health problems. In her Mental Health Minute, Judith Feld, MD, MPH, MMM, DLFAPA (and National Medical Director at Ontrak) discusses a recent paper, “
Advertisement
Related to this article
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
New Adult ADHD Guidelines: What Resources Are Coming Soon
3
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5